Lauran Neergaard | Associated Press
-
Federal scientists say kid-size doses of Pfizer’s COVID-19 vaccine appear highly effective at preventing symptomatic infections among elementary school children. The Food and Drug Administration posted its review late Friday ahead of a public meeting to consider opening vaccinations to kids 5 to 11.